Study links prediabetes remission to lower diabetes risk without weight loss

8. Oktober 2025 Von KI berichtet

Researchers in Tübingen have found that people with prediabetes can reduce their risk of developing type 2 diabetes by 71% through lifestyle changes that normalize blood sugar levels, even if they do not lose weight. The study emphasizes the role of improved fat distribution over mere weight reduction. This challenges current guidelines focused primarily on shedding pounds.

Higher semaglutide dose boosts weight loss in obesity trials

Two phase 3 clinical trials show that a 7.2 mg weekly dose of semaglutide leads to greater weight loss than the approved 2.4 mg dose in adults with obesity, including those with type 2 diabetes. Nearly half of participants on the higher dose lost 20% or more of their body weight over 72 weeks. The results, published in The Lancet Diabetes & Endocrinology, suggest improved metabolic health with a favorable safety profile.

Study highlights disparities in obesity care access

4. Oktober 2025 Von KI berichtet

A recent analysis reveals significant gaps in obesity treatment for certain demographic groups in the United States. Researchers found that access to care varies widely based on race, income, and location, underscoring ongoing challenges in healthcare equity.

Ende des Patentschutzes für Abnehmspritzen begünstigt Patienten

3. Oktober 2025 Von KI berichtet

Der Patentschutz für das Wirkstoff Semaglutid in Abnehmspritzen wie Ozempic und Wegovy läuft in Europa aus. Das ermöglicht den Markteintritt günstiger Generika und könnte die hohen Preise senken. Patienten mit Adipositas profitieren von besserer Verfügbarkeit.

Scientists discover protein that switches off hunger

Researchers have identified how a protein called MRAP2 regulates hunger by transporting the brain receptor MC4R to the cell surface, enhancing appetite-suppressing signals. This finding, from a study involving institutions in Germany, Canada, and the UK, could lead to new obesity treatments. The work was published in Nature Communications.